• The company develops its own products by encapsulating molecules or enzymes already present on the market and whose therapeutic potential could be enhanced through encapsulation.
• It also works with partners to sign strategic co-development alliances within the pharma market, notably for molecules whose pre-clinical development was stopped due to toxicity.

The high potential of ERYtech Pharma’s products lies in the fact that they fit into existing therapeutic recommandations for physicians.